(248 days)
Not Found
No
The device description outlines a microarray-based gene expression analysis and a calculation based on correlation to a template, which are standard bioinformatics techniques and do not inherently involve AI/ML. There is no mention of AI, ML, or related terms in the summary.
No.
The document states that MammaPrint is a "qualitative in vitro diagnostic test service" and "is indicated for use by physicians as a prognostic marker only." It assesses risk and provides information, but does not directly treat or alleviate a disease or condition.
Yes
Explanation: The "Intended Use / Indications for Use" section explicitly states that MammaPrint is a "qualitative in vitro diagnostic test service." It is used to assess a patient's risk for distant metastasis in breast cancer patients.
No
The device description clearly outlines a process involving physical components like microarrays, scanners, and laboratory procedures for RNA isolation and hybridization. While software is used for data acquisition and calculation, it is an integral part of a larger hardware-based system.
Yes, this device is an IVD (In Vitro Diagnostic).
Here's why:
- Explicitly stated in the Intended Use: The very first sentence of the "Intended Use / Indications for Use" section clearly states: "MammaPrint is a qualitative in vitro diagnostic test service..."
- Performed in a central laboratory: This indicates the test is performed on biological samples outside of the patient's body.
- Uses biological samples: The test uses "fresh breast cancer tissue samples."
- Provides diagnostic information: The test assesses a patient's risk for distant metastasis, which is a diagnostic assessment.
The description of the device and its processes further supports this, detailing the analysis of RNA from tumor tissue.
N/A
Intended Use / Indications for Use
MammaPrint is a qualitative in vitro diagnostic test service, performed in a central laboratory, using the gene expression profile of fresh breast cancer tissue samples to assess a patient's risk for distant metastasis (up to 10 years for patients less than 61 years old, up to 5 years for patients' ≥ 61 years).
The test is performed for breast cancer patients with Stage I or Stage II disease, with tumor size 7). Isolations were performed on three different days, twelve samples each day, in total 36 samples.
PART 2: AMPLIFICATION/LABELING AND HYBRIDIZATION
For validation of the labeling, amplification and hybridization steps of MammaPrint at the US lab (Lab 2). RNA from 99 samples was used. All samples had been previously subjected to a diagnostic MammaPrint test at the Amsterdam Lab (Lab 1). Based on the Amsterdam result the following result distribution was selected:
- High risk: n=54 (54.5%)
- Low risk: n=38 (38.3%)
- Borderline: n=7 (7.1%)
RNA was amplified, labeled and hybridized according to standard MammaPrint protocols on FDA cleared MammaPrint Low (HD) 8-pack array. The 99 samples the standard control samples (Low Risk Control and High Risk Control) were analyzed. To show MammaPrint stability over time and to determine variation in MammaPrint Index, LRC and HRC were analyzed on each labeling day and on additional days resulting in 20 data points per control sample.
Statistical analysis performed: Passing and Bablok regression analysis, Bland & Altman analysis, McNEMARS TEST, Analysis on Control Pools: LRC AND HRC.
Key Result: The studies show that there is no significant difference in RNA quality of RIN measurement between Amsterdam (L1) and US lab (L2). All results comply with the predefined validation acceptance criteria as described in the validation plan. Moreover when comparing of MammaPrint Index and Outcome, it is concluded that there is no significant difference in MammaPrint Indices between European / Dutch (L1) and US / California (L2) lab. All results comply with the predefined validation acceptance criteria as described in the validation plan.
Key Metrics (Sensitivity, Specificity, PPV, NPV, etc.)
Not Found
Predicate Device(s): If the device was cleared using the 510(k) pathway, identify the Predicate Device(s) K/DEN number used to claim substantial equivalence and list them here in a comma separated list exactly as they appear in the text. List the primary predicate first in the list.
Reference Device(s): Identify the Reference Device(s) K/DEN number and list them here in a comma separated list exactly as they appear in the text.
Not Found
Predetermined Change Control Plan (PCCP) - All Relevant Information for the subject device only (e.g. presence / absence, what scope was granted / cleared under the PCCP, any restrictions, etc).
Not Found
§ 866.6040 Gene expression profiling test system for breast cancer prognosis.
(a)
Identification. A gene expression profiling test system for breast cancer prognosis is a device that measures the ribonucleic acid (RNA) expression level of multiple genes and combines this information to yield a signature (pattern or classifier or index) to aid in prognosis of previously diagnosed breast cancer.(b)
Classification. Class II (special controls). The special control is FDA's guidance document entitled “Class II Special Controls Guidance Document: Gene Expression Profiling Test System for Breast Cancer Prognosis.” See § 866.1(e) for the availability of this guidance document.
0
Section 5: 510(k) Summary
| 1. Assigned 510(k) number | |
|---|---|
| The assigned 510(k) number is |
JAN 2 8 2011
- Company
Agendia BV Science Park 406 1098XH Amsterdam The Netherlands Telephone : 31 20 462 1500
- Contact
Guido Brink, Senior Director Regulatory Affairs and Quality Assurance
- Date Prepared
May 21, 2010
- Proprietary Name
MammaPrint®
6. Classification Name
Gene expression profiling test system, for breast cancer prognosis.
7. Common Name
Multivariate device for cancer prognosis
8. Classification
Class II, regulated under 21 CFR 866.6040, product code NYI
9. Predicate Device
Agendia BV's MammaPrint (K081092)
1
10. Device Description
The MammaPrint service is a microarray based gene expression analysis of a tumor. The analysis is based on several processes: isolation of RNA from frozen tumor tissue sections. DNA'se treatment of isolated RNA, linear amplification and labeling of DNA'se treated RNA, cRNA purification, hybridization of the cRNA to the MammaPrint microarray, scanning the MammaPrint microarray and data acquisition (feature extraction), calculation and determination of the risk of recurrence in breast cancer patients.
The MammaPrint analysis is designed to determine the gene activity of specific genes in a tissue sample compared to a reference standard. The result is an expression profile, or fingerprint, of the sample.
The correlation of the sample expression profile to a template (the mean expression profile of 44 tumors with a known good clinical outcome) is calculated and the molecular profile of the sample is determined (Low Risk, High Risk).
11. Intended Use
MammaPrint is a qualitative in vitro diagnostic test service, performed in a central laboratory, using the gene expression profile of fresh breast cancer tissue samples to assess a patient's risk for distant metastasis (up to 10 years for patients less than 61 years old, up to 5 years for patients' ≥ 61 years).
The test is performed for breast cancer patients with Stage I or Stage II disease, with tumor size 7). Isolations were performed on three different days, twelve samples each day, in total 36 samples.
PART 2: AMPLIFICATION/LABELING AND HYBRIDIZATION
For validation of the labeling, amplification and hybridization steps of MammaPrint at the US lab (Lab 2). RNA from 99 samples was used. All samples have been previously subjected to a diagnostic MammaPrint test at the Amsterdam Lab (Lab 1). Based on the Amsterdam result the following result distribution was selected:
- Hiah risk: n=54 (54.5%) -
- । Low risk: n=38 (38.3%)
- -Borderline: n=7 (7.1%)
RNA was amplified, labeled and hybridized according to standard MammaPrint protocols on FDA cleared MammaPrint Low (HD) 8-pack array.
The 99 samples the standard control samples (Low Risk Control and High Risk Control) were analyzed. To show MammaPrint stability over time and to determine variation in MammaPrint Index, LRC and HRC were analyzed on each labeling day and on additional days resulting in 20 data points per control sample.
4
Statistical analysis that have been performed on the data are:
- . Passing and Bablok regression analysis
- . Bland & Altman analysis
- McNEMARS TEST
- . Analysis on Control Pools: LRC AND HRC
The studies show that there is no significant difference in RNA quality of RIN measurement between Amsterdam (L1) and US lab (L2). All results comply with the predefined validation acceptance criteria as described in the validation plan.
Moreover when comparing of MammaPrint Index and Outcome, it is concluded that there is no significant difference in MammaPrint Indices between European / Dutch (L1) and US / California (L2) lab. All results comply with the predefined validation acceptance criteria as described in the validation plan.
14. Conclusion
MammaPrint is a clinically and analytically accurate prognostic marker for providing a risk assessment of distant metastasis of breast cancer when performed in either Agendia's European or US central laboratory.
5
Image /page/5/Picture/1 description: The image shows the logo for the U.S. Department of Health & Human Services. The logo consists of a circular seal with the text "DEPARTMENT OF HEALTH & HUMAN SERVICES • USA" around the perimeter. Inside the circle is an emblem featuring a stylized human figure with outstretched arms, representing care and protection.
Public Health Service
Food and Drug Administration 10903 New Hampshire Avenue Silver Spring, MD 20993
Agendia BV c/o Mr. Guido Brink Director, Regulatory Affairs Science Park 406 1098 XH Amsterdam The Netherlands
JAN 2 8 2011
Re: K101454
Trade/Device Name: MammaPrint® Regulation Number: 21 CFR§866.6040 Regulation Name: expression profiling test system for breast cancer prognosis Regulatory Class: Class II Product Code: NYI Dated: December 23, 2010 Received: December 27, 2010
Dear Mr. Brink:
We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drig, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.
If your device is classified (see above) into class II (Special Controls), it may be subject to such additional controls. Existing major regulations affecting your device can be found in Title 21, Code of Federal Regulations (CFR), Parts 800 to 895. In addition, FDA may publish frinther announcements concerning your device in the Federal Register.
Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must
6
Page 2 – Mr. Guido Brink
comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Parts 801 and 809); medical device reporting (reporting of medical device-related adverse events) (21 CFR 803); and good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820). This letter will allow you to begin marketing your device as described in your Section 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.
ff you desire specific advice for your device on our labeling regulation (21 CFR Parts 801 and 809), please contact the Office of In Vitro Diagnostic Device Evaluation and Safety at (301) 796-5450. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to http://www.fda.gov/MedicalDevices/Safety/ReportaProblem/default.htm for the CDRH's Office of Surveillance and Biometrics/Division of Postmarket Surveillance.
You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 796-7100 or at its Internet address http://www.fda.gov/cdrh/industry/support/index.html.
Sincerely yours,
M Chan
Maria M. Chan, Ph.D. Director · Division of Immunology and Hematology Devices Office of In Vitro Diagnostic Device Evaluation and Safety Center for Devices and Radiological Health
Enclosure
7
Image /page/7/Picture/15 description: The image shows a logo with the word "agenda" in a stylized font. Above the word "agenda" is a graphic that resembles a fingerprint or a stylized representation of a brain. Below the word "agenda" is a smaller text, which is difficult to read due to the image quality.
ection 4: Indications for Use Statement
Indications for Use Form
K101454 510(k) Number (if known):
Device Name: MammaPrint®
Indications for Use:
MammaPrint is a qualitative in vitro diagnostic test service, performed in a central laboratory, using the gene expression profile of fresh breast cancer tissue samples to assess a patients' risk for distant metastasis (up to 10 years for patients less than 61 years old, up to 5 years for patients' ≥ 61 years).
The test is performed for breast cancer patients with Stage I or Stage II disease, with a tumor size of ≤ 5.0 cm and lymph node negative. The MammaPrint result is indicated for use by physicians as a prognostic marker only, along with a other clinicopathological factors.
Prescription Use XX (Part 21 CFR 801 Subpart D) AND/OR
Over-The-Counter Use (21 CFR 801 Subpart C)
(PLEASE DO NOT WRITE BELOW THIS LINE-CONTINUE ON ANOTHER PAGE OF NEEDED)
Concurrence of CDRH, Office of Device Evaluation (ODE)
| Page 1 of 1 | |||
|---|---|---|---|
| Division Sign-Off |
Office of In Vitro Diagnostic
Device Evaluation and Safety
| K101454 | ||
|---|---|---|
| -- | --------- | -- |
Agendia BV - Amsterdam 2010-1061 Additional Scanner